Search research articles
Contact Us
Filters
Showing results (1-10 of 57) with videos related to
Page
of 6
Sort By:
Diabetes Research and Clinical Practice
|
June 17, 2023
Perspectives in weight control in diabetes - Survodutide
Thomas Klein, Robert Augustin, Anita M Hennige
Diabetes, Obesity & Metabolism
|
March 28, 2023
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity
Rie Yazawa, Masahiro Ishida, Yesilda Balavarca, et al.
Plos One
|
September 3, 2016
Sustained Treatment with Insulin Detemir in Mice Alters Brain Activity and Locomotion
Tina Sartorius, Anita M Hennige, Andreas Fritsche, et al.
Diabetologia
|
December 14, 2023
Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Matthias Blüher, Julio Rosenstock, Josef Hoefler, et al.
Journal of Pharmacological and Toxicological Methods
|
March 18, 2014
Monitoring the stress-level of rats with different types of anesthesia: a tail-artery cannulation protocol
Dávid Z Balla, Saskia Schwarz, Hannes M Wiesner, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
March 10, 2005
Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt
Cora Weigert, Anita M Hennige, Katrin Brodbeck, et al.
Diabetes, Obesity & Metabolism
|
October 7, 2024
A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesity
Nadine Beetz, Brigitte Kalsch, Thomas Forst, et al.
Regulatory Peptides
|
June 24, 2008
Effect of insulin detemir, compared to human insulin, on 3T3-L1 adipogenesis
Anja Böhm, Harald Staiger, Anita M Hennige, et al.
Plos One
|
May 13, 2015
The brain response to peripheral insulin declines with age: a contribution of the blood-brain barrier?
Tina Sartorius, Andreas Peter, Martin Heni, et al.
Plos One
|
March 13, 2008
Fetuin-A induces cytokine expression and suppresses adiponectin production
Anita M Hennige, Harald Staiger, Corinna Wicke, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 57) with videos related to
Sort By:
Page
of 6
Diabetes Research and Clinical Practice
|
June 17, 2023
Perspectives in weight control in diabetes - Survodutide
Thomas Klein, Robert Augustin, Anita M Hennige
Diabetes, Obesity & Metabolism
|
March 28, 2023
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity
Rie Yazawa, Masahiro Ishida, Yesilda Balavarca, et al.
Plos One
|
September 3, 2016
Sustained Treatment with Insulin Detemir in Mice Alters Brain Activity and Locomotion
Tina Sartorius, Anita M Hennige, Andreas Fritsche, et al.
Diabetologia
|
December 14, 2023
Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Matthias Blüher, Julio Rosenstock, Josef Hoefler, et al.
Journal of Pharmacological and Toxicological Methods
|
March 18, 2014
Monitoring the stress-level of rats with different types of anesthesia: a tail-artery cannulation protocol
Dávid Z Balla, Saskia Schwarz, Hannes M Wiesner, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
March 10, 2005
Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt
Cora Weigert, Anita M Hennige, Katrin Brodbeck, et al.
Diabetes, Obesity & Metabolism
|
October 7, 2024
A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesity
Nadine Beetz, Brigitte Kalsch, Thomas Forst, et al.
Regulatory Peptides
|
June 24, 2008
Effect of insulin detemir, compared to human insulin, on 3T3-L1 adipogenesis
Anja Böhm, Harald Staiger, Anita M Hennige, et al.
Plos One
|
May 13, 2015
The brain response to peripheral insulin declines with age: a contribution of the blood-brain barrier?
Tina Sartorius, Andreas Peter, Martin Heni, et al.
Plos One
|
March 13, 2008
Fetuin-A induces cytokine expression and suppresses adiponectin production
Anita M Hennige, Harald Staiger, Corinna Wicke, et al.
Page
of 6